

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/062482-2025>

Contract

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS England

UK7: Contract details notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2025/S 000-062482

Procurement identifier (OCID): ocds-h6vhtk-055064 ([view related notices](#))

Published 6 October 2025, 12:40pm

Scope

Reference

C346388

Description

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

Offer reference number: CM/PHS/25/5728

Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Potential periods of call-offs under the framework agreement:

CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

7NAT (National) 01/12/2025 to 31/05/2027 (18 months)

CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments
aflibercept 2mg:

NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months)

SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months)

MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months)

LNW: (London) 01/12/2025 to 31/05/2027 (18 months)

Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brotacizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of;

- neovascular (wet) age-related macular degeneration (AMD)
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)
- proliferative diabetic retinopathy (PDR)
- visual impairment due to diabetic macular oedema (DME)
- visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- vision impairment associated with chronic diabetic macular oedema, (DME)
- visual impairment due to myopic choroidal neovascularisation (myopic CNV)
- retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease
- inflammation of the posterior segment of the eye presenting as non-infectious uveitis
- prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye

Commercial tool

Establishes a framework

Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

Description

CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:
7NAT (National)

Framework

Maximum percentage fee charged to suppliers

0%

Framework operation description

Please refer to the ITO Documents for the Operation Description.

Award method when using the framework

Without competition

Contracting authorities that may use the framework

Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points

Contracting authority location restrictions

- UK - United Kingdom
-

Contract 2. Lot 1 - CM/PHS/25/5728/01

Lots

Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

Suppliers (10)

- [Abbvie Ltd](#)
- [Alimera Sciences](#)
- [Bayer Plc](#)
- [Biogen](#)
- [Novartis Pharmaceuticals UK Ltd](#)

- [Orion Pharma \(UK\) Ltd](#)
- [Outlook Therapeutics, Inc.](#)
- [Roche Products Ltd](#)
- [Teva UK Limited](#)
- [Thornton and Ross Ltd](#)

Contract value

- £688,834,174 excluding VAT
- £826,601,009 including VAT

Above the relevant threshold

Date signed

22 September 2025

Contract dates

- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029
- 3 years, 6 months

Description of possible extension:

option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Main procurement category

Goods

CPV classifications

- 33600000 - Pharmaceutical products

Key performance indicators

Name	Description	Reporting frequency
Buffer Stock requirement	6 months Buffer Stock	3 months

Signed contract documents

[Framework Agreement and Terms and Conditions - Lot 1.pdf](#)

Framework Agreement and Terms and Conditions - Lot 1

Contract 3. Lot 2 - CM/PHS/25/5728/02

Lots

Lot 1. CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:

Suppliers (5)

- [Bayer Plc](#)
- [BIOSIMILAR COLLABORATIONS IRELAND LIMITED](#)

- [Celltrion Healthcare United Kingdom Limited](#)
- [MDBIOLOGICS LTD](#)
- [SANDOZ LIMITED](#)

Contract value

- £782,917,972 excluding VAT
- £939,501,566 including VAT

Above the relevant threshold

Date signed

22 September 2025

Contract dates

- 1 December 2025 to 31 May 2027
- Possible extension to 31 May 2029
- 3 years, 6 months

Description of possible extension:

option or options to extend (at the discretion of the Authority) up to maximum of 24 months.

Main procurement category

Goods

CPV classifications

- 33600000 - Pharmaceutical products

Key performance indicators

Name	Description	Reporting frequency
Buffer Stock	6 months Buffer Stock	3 months

Signed contract documents

[Framework Agreement and Terms and Conditions - Lot 2.pdf](#)

Framework Agreement and Terms and Conditions - Lot 2

Other information

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Open procedure

Suppliers

Abbvie Ltd

- Public Procurement Organisation Number: PHRQ-1133-WGCH

Abbvie House Vanwall Business Park

Maidenhead

SL6 4UB

United Kingdom

Email: val.stenning@abbvie.com

Region: UKJ11 - Berkshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Alimera Sciences

- Public Procurement Organisation Number: PYCZ-7339-TCCT

Form 1 Bartley Wood Business Park

Hook

RG27 9XA

United Kingdom

Email: catherine.griffiths@alimerasciences.com

Region: UKJ37 - North Hampshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Bayer Plc

- Public Procurement Organisation Number: PWRY-2527-LDRY

400 South Oak Way

Reading

RG2 6AD

United Kingdom

Email: andrew.asbury@bayer.com

Region: UKJ11 - Berkshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 3. Lot 2 - CM/PHS/25/5728/02

Bayer Plc

- Companies House: 00935048

400 South Oak Way

Reading

RG26AD

United Kingdom

Email: andrew.asbury@bayer.com

Region: UKJ11 - Berkshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Biogen

- Public Procurement Organisation Number: PTGT-3385-PBMQ

Building 5 Foundation Park

Maidenhead

SL63UD

United Kingdom

Email: bbumarketaccessuk@biogen.com

Region: UKJ11 - Berkshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

BIOSIMILAR COLLABORATIONS IRELAND LIMITED

- Public Procurement Organisation Number: PQQC-5869-LMVX

Biocon Biologics 16 Great Queen Street

London

WC2B 5AH

United Kingdom

Email: uk_tenders@biocon.com

Region: UKI31 - Camden and City of London

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 3. Lot 2 - CM/PHS/25/5728/02

Celltrion Healthcare United Kingdom Limited

- Public Procurement Organisation Number: PYQL-4248-PXXY

Celltrion Healthcare UK Limited, The Charter Building, Charter Place

Uxbridge

UB8 1JG

United Kingdom

Email: james.potter@celltrionhc.com

Region: UKI74 - Harrow and Hillingdon

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 3. Lot 2 - CM/PHS/25/5728/02

MDBIOLOGICS LTD

- Public Procurement Organisation Number: PMHC-1596-RTNX

71-75 Shelton Street

London

WC2H 9JQ

United Kingdom

Email: paul.clark@mdbiologics.co.uk

Region: UKI31 - Camden and City of London

Small or medium-sized enterprise (SME): Yes

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 3. Lot 2 - CM/PHS/25/5728/02

Novartis Pharmaceuticals UK Ltd

- Public Procurement Organisation Number: PJTX-5182-QVLR

2nd Floor, The Westworks Building White City Place

London

W12 7FQ

United Kingdom

Email: commercial.team@novartis.com

Region: UKI33 - Kensington & Chelsea and Hammersmith & Fulham

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Orion Pharma (UK) Ltd

- Public Procurement Organisation Number: PJZQ-1429-ZBVY

The Scalpel, 18th Floor

London

EC3M 7AF

United Kingdom

Email: mark.soderberg@orionpharma.com

Region: UKI31 - Camden and City of London

Small or medium-sized enterprise (SME): Yes

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Outlook Therapeutics, Inc.

- Public Procurement Organisation Number: PGZH-1763-NPGX

3rd Floor One London Square, Cross Lanes, Guildford,

Surrey

GU1 1UN

United Kingdom

Email: uktenders@outlooktherapeutics.com

Region: UKJ25 - West Surrey

Small or medium-sized enterprise (SME): Yes

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Roche Products Ltd

- Public Procurement Organisation Number: PXCG-4172-CHYM

6 Falcon Way

Welwyn Garden City

AL7 1TW

United Kingdom

Email: welwyn.rx_bdop@roche.com

Region: UKH23 - Hertfordshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

SANDOZ LIMITED

- Public Procurement Organisation Number: PNQL-1548-CYBZ

Maxis 1, Western Road

Bracknell

RG12 1RF

United Kingdom

Email: uk.hosp@sandoz.com

Region: UKJ11 - Berkshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 3. Lot 2 - CM/PHS/25/5728/02

Teva UK Limited

- Public Procurement Organisation Number: PWDD-6894-DXRM

Ridings Point

Castleford

WF10 5HX

United Kingdom

Email: chrissie.kellett@tevauk.com

Region: UKE45 - Wakefield

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Thornton and Ross Ltd

- Public Procurement Organisation Number: PWYH-6892-QYNN

Linthwaite Labs Manchester Road

Huddersfield

HD7 5QH

United Kingdom

Email: rachelwright@thorntonross.com

Region: UKE44 - Calderdale and Kirklees

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 2. Lot 1 - CM/PHS/25/5728/01

Contracting authority

NHS England

- Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Contact name: Balram Kullootee

Email: b.kullootee@nhs.net

Website: <https://www.england.nhs.uk/>

Region: UKI45 - Lambeth

Organisation type: Public authority - central government